Q2 2025 Merit Medical Systems Inc Earnings Call

Welcome to the Merit Medical Systems Q2 2025 earnings conference call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded, and that the recording will be available on the company's website for replay shortly.

I would now like to turn the call over to Mr. Fred lampropoulos. Merit Medical Systems founder, chairman and chief executive officer. Please go ahead.

Fred Lampropoulos: Thank you and welcome, everyone. I am joined on the call today by Raul Parra, our chief financial officer and treasurer, and Brian Lloyd, our chief legal officer and corporate secretary. Brian, would you mind taking us through the Safe Harbor statements, please?

Thank you, and welcome everyone. I am joined on the call today by Rahul para, our Chief Financial Officer and Treasurer and Brian Lloyd. Our chief legal officer in corporate secretary,

Raul Parra: Thank you, Fred. This presentation contains forward-looking statements that receive Safe Harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties. The realization of any of these risks or uncertainties, as well as extraordinary events or transactions impacting our company, could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking statements. In addition, any forward-looking statements represent our views only as of today, July 30th, 2025, and should not be relied upon as representing our views as of any other date. We specifically disclaim any obligation to update such statements except as required by applicable law. Please refer to the sections entitled Cautionary Statement Regarding Forward-Looking Statements in today's press release and presentation for important information regarding such statements.

Brian, would you mind taking us through the Safe Harbor statements, please

Thank you, Fred.

This is presentation contains forward-looking statements that receive Safe, Harbor, protection under Federal Securities laws.

Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties.

The realization of any of these risks or uncertainties, as well as extraordinary events or transactions impacting our company, could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking statements.

In addition.

Any forward-looking statements represent our views only as of today, July 30, 2025, and should not be relied upon as representative of views as of any other date.

We specifically disclaim any obligation to update such statements, except as required by applicable law.

Raul Parra: For discussion of factors that could cause actual results to differ from these forward-looking statements, please also refer to our most recent findings with the SEC, which are available on our website. Our financial statements are prepared in accordance with accounting principles, which are generally accepted in the United States. However, we believe certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of our ongoing operations and can be useful for period-over-period comparisons of such operations. This presentation also contains certain non-GAAP financial measures. A reconciliation of non-GAAP financial measures to the most directly comparable US GAAP measures is included in today's press release and presentation furnished to the SEC under Form 8K. Please refer to the sections of our press release and presentation entitled Non-GAAP Financial Measures for important information regarding non-GAAP financial measures discussed on this call.

Please refer to the sections entitled "Cautionary Statement Regarding Forward-Looking Statements" in today's press release and presentation for important information regarding such statements.

For discussion of factors that could cause actual results to differ from these forward-looking statements, please also refer to our most recent findings with the SEC which are available on our website.

Our financial statements are prepared in accordance with the county principles, which are generally accepted in the United States.

However we believe certain non-gaap Financial measures provide investors with useful information regarding the underlying business Trends and performance of our ongoing operations.

And can be useful for period over period comparisons of such operations.

This presentation also contains certain non-gaap Financial measures.

Our reconciliation of non-gaap financial measures to the most directly comparable us. Gaap measures is included in today's press release and presentation furnished to the SEC under Form 8K.

Raul Parra: Readers should consider non-GAAP financial measures in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. Please note that these calculations may not be comparable with similarly titled measures of other companies. Both today's press release and our presentation are available on the investors' page of our website. I will now turn the call back to Fred.

Please refer to the sections of our press release and presentation, entitled non-gaap Financial measures for important information. Regarding non-gaap Financial measures discussed on this call.

Readers should consider non-gaap Financial measures in addition to not as a substitute for financial reporting measures prepared in accordance with gaap.

Please note that these calculations may not be comparable with similarly titled measures of other companies.

Both today's press release and our presentation are available available on the investors page of our website.

Fred Lampropoulos: Thank you, Brian. Let me start with a brief agenda of what we will cover during our prepared remarks. I will start with a summary of our second quarter 2025 financial results. I will then discuss two important strategic announcements we made during the second quarter and will provide an update on our reimbursement strategy for the Rap City CIE. Then Raul will provide a more in-depth review of our quarterly financial results and our financial guidance for 2025, which we updated in today's press release. Then we will open the call for your questions. Beginning with the review of our second quarter results, we reported total revenue of 382.5 million, up 13% year-over-year on a GAAP basis, and up 12.5% year-over-year on a constant currency basis.

I will now turn the call back to Fred.

Thank you Brian. Let me start with a brief agenda of what we will cover uh during our prepared remarks.

I will start with a summary of our second quarter, 2025 Financial results.

I will then discuss 2 important, strategic announcements announcements we made during the second quarter and we'll provide an update on our reimbursement strategy for the Rap City cie.

Then Raoul will provide a more in-depth review of our quarterly Financial results and our financial guidance for 2025

Which we updated in today's press release.

Then we will open the call for your questions.

Beginning with the review of our second quarter results.

Fred Lampropoulos: The constant currency revenue growth we delivered in the second quarter exceeded the high end of the range of growth expectations that we outlined on our Q1 2025 earnings call. The better-than-expected constant currency revenue results were driven by a 6.7% constant currency organic growth, which exceeded the 6% high end of the range we outlined in our second quarter guidance. With respect to our profitability performance in the second quarter, we delivered financial results that significantly exceeded our expectations. We delivered another quarter of notable year-over-year improvement in our non-GAAP operating margin, which increased nearly 109 basis points year-over-year to a 21.2%, representing the highest non-GAAP operating margin performance in any quarter in the company's history as a public company.

Percent year-over-year on a constant currency basis.

The constant currency Revenue growth. We delivered in the second quarter, exceeded the high end of the range of growth expectations that we outlined on our quarter. 1 2025 earnings call.

The better-than-expected constant currency revenue results were driven by a 6.7% constant currency organic growth.

Which exceeded the 6% high end of the range. We outlined in our second quarter guidance.

With respect to our profitability performance. In the second quarter, we delivered Financial results that significantly exceeded our expectations.

Fred Lampropoulos: We also delivered 10% growth in our non-GAAP EPS, which exceeded the high end of our expectations, and we generated $70 million of free cash flow, an increase of 20% year-over-year. This performance was a direct result of the team's continued hard work and commitment to our strategic objectives. We're very proud of the strong execution our team delivered in the second quarter of 2025. We believe our second quarter results reflect continued strong momentum in the business, and we are confident in our team's ability to deliver the total revenue guidance for 2025 we updated in today's press release. Despite the continued challenges related to the dynamic and uncertain global macro environment, our team is executing well.

We delivered another quarter of notable year-over-year improvement in our non-gaap, operating margin, which increased nearly 109 basis points year-over-year to a 21.2% representing the highest non-gaap operating. Margin performance in any quarter in the company's history as a public company.

We also delivered 10% growth in our non-GAAP.

EPS which exceeded the high end of our expectations.

And we generated seventy million dollars of free cash flow and increase of 20% year-over-year.

Performance was a direct result of the teams continued hard work and commitment to our strategic objectives.

We're very proud of the strong execution. Our team delivered in the second quarter of 2025.

We believe our second quarter results, reflect continued, strong momentum in the business, and we are confident in our, uh, team's ability to deliver. The total revenue guidance for 2025. We updated in today's press release.

Fred Lampropoulos: We remain focused on delivering continued strong execution, solid constant currency growth, and strong free cash flow generation in 2025, as well as continued progress in our Continued Growth Initiative program and related financial targets for the three-year period ending December 31, 2026. Turning to a discussion on two key announcements we made since our last earnings call. On May 20, 2025, we announced the acquisition of BioLife Delaware LLC for aggregate transaction consideration paid in cash and an assumption of liabilities of $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance. BioLife, headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal. These products are effective, differentiated hemostatic solutions for percutaneous devices with a broad range of clinical applications, including vascular closure and indwelling catheter bleeding complications.

Despite the continued challenges related to the dynamic and uncertain Global macro environment, our team is executing well.

We remain focused on, delivering continued, strong execution.

Solid constant currency growth and strong free cash flow generation in 2025 as well as continued progress. And our continued growth Initiative Program and related Financial targets for the 3-year period, and in December, 312022.

turning to a discussion on 2 key announcements, we made um since our last earnings call

On May 20, 2025, we announced the acquisition of BioLife Delaware, LLC.

for aggregate transaction consideration, paid in cash and an assumption of liabilities of $120 million.

This strategic acquisition positions, Merit

to provide clinicians with more products designed to standardize simplify and minimize post procedure care and maintenance

By a life headquartered in Sarasota, Florida.

Manufacturers unique patented Heist devices under the brand name, stats, seal and wound. Seal

Fred Lampropoulos: Sales of BioLife products generated approximately $15 million of revenue over the 12-month period ended December 31, 2024, and we believe these products will have a significant potential growth opportunity as they penetrate an estimated $350 million global addressable market. Many Merit products operate through small openings in the skin that require efficient solutions to stop bleeding, promote patient recovery, and minimize costly complications. In such cases, StatSeal specifically works with the patient's blood to rapidly form a protective seal over the procedure site. Adding StatSeal to Merit's hemostatic portfolio is intended to provide healthcare partners with an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology, dialysis, electrophysiology, biopsy, and drainage. On July 7th, we announced the appointment of Martha Aronson as Merit's new president and chief executive officer, effective October 3rd, 2025.

These products are effective, differentiated hemostatic solutions, for percutaneous devices with a broad range of clinical applications, including vascular closure. And indwelling catheter bleeding complications

Sales of violife products generated approximately 15 million dollars of Revenue over the 12-month period ended December 31st 2024. And we believe these products will have a significant, a significant potential growth opportunity as they penetrate an estimated 350 million Global addressable Market.

Many Merit products operate through small openings in the skin that require efficient solutions to stop bleeding, promote patient recovery and minimize costly complications.

In such cases, stat sales specifically work with the patients' blood to rapidly form a protective seal over the procedure site.

Adding stats sealed to merits heo, static portfolio is intended to provide Health Care Partners with an additional effective solution that complements a wide range of percutaneous procedures, including Interventional Radiology, and Cardiology dialysis electrophysiology biopsy. And drainage

On July 7th.

Fred Lampropoulos: I'm very excited to welcome Martha to Merit and believe that she is uniquely qualified to lead the company into the future. As discussed on prior calls, the board executed a thorough search and a selection process as part of our CEO succession strategy. Martha brings extensive expertise and understanding of the industry, and more importantly, she was identified as an exceptional fit for the organization, consistent with the Merit way, which we believe makes her the ideal leader for Merit's next stage of growth. I will continue to serve as president and CEO and chairman of the board through October 3rd, 2025. Upon Martha's appointment, I will continue to serve as chairman of the board. I would like now to provide an update on our commercial strategy for the Rap City CIE in the United States.

2025.

Yeah, I'm very excited to welcome Martha to Merit and believe that she is uniquely qualified to leave the company into the future.

As discussed on prior calls, the board, executed a thorough search and a selection process as part of our CEO succession strategy.

Martha brings extensive expertise and understanding of the industry, and more importantly, she was identified as an exceptional fit for the organization. Consistent with the Merit way, we believe she is the ideal leader for the next stage of growth.

I will continue to serve as President and CEO and Chairman of the Board through October 3, 2025.

Upon Martha's appointment. I will continue to serve as chairman of the board.

Fred Lampropoulos: As outlined on our investor call in January, our renal therapies group launched the US commercial strategy for Rap City CIE following our PMA approval last December. This strategy is comprehensive and multifaceted, including a comprehensive marketing plan focused on raising awareness and expanding upon the existing strong physician relationships and clinical partnerships supporting the current RTG portfolio offering, engaging with new and existing customers to work through the back approval processes, as well as working with the largest GPOs and some of the largest IDNs across the country, and hosting physician training events at centers of excellence with physician partners who are passionate about the product and educating their peers on the benefits of the Rap City CIE.

I would like, uh, now to provide an update on our commercial strategy for the rap city cie in the United States.

As outlined on our investor call in January, our renal therapist group launched the U.S. commercial strategy for Rap City C.I.A. following our PMA approval last December.

this strategy is comprehensive and multifaceted including

a contrib, a comprehensive marketing plan focused on raising awareness and expanding upon the existing strong physician relationships and clinical Partnerships supporting the current RTG portfolio offering

Fred Lampropoulos: The RTG team has executed the US commercial strategy for Rap City CIE well during 2025, and more importantly, they have exceeded our expectations with respect to leveraging the new access to customers from the early commercialization of Rap City CIE to identify opportunities to drive adoption and utilization of the rest of our dialysis product portfolio. By way of reminder, our pricing strategy is an important input to our US commercial strategy for Rap City CIE. Specifically, our go-to-market strategy is based on selling the Rap City CIE at a premium price relative to the competitive coverage stance offered in the US today. We believe the Rap City CIE is a completely new treatment option for patients, as evidenced by our breakthrough designation from the FDA.

Engaging with new and existing customers to work through the back approval processes, as well as working with the largest GPOs and some of the largest IBMs across the country. Additionally, hosting physician training events at Centers of Excellence with physician partners who are passionate about the product and educating their peers on the benefits of the Rapid City CIE.

The RTG team has executed the U.S. commercial strategy. Perhaps the CIA, well, during 2025.

And, more importantly, they have exceeded our expectations with respect to leveraging the new access to customers.

From the early, commercialization of wraps City cie to identify opportunities to drive adoption and utilization of the rest of our dialysis product portfolio.

By way of reminder, our pricing strategy is an important input to our us commercial strategy for Rapid cie.

Specifically our go to market strategy is based on selling the rapid cie at a premium price relative to the competitive coverage dense offered in the US today.

Fred Lampropoulos: The Rap City CIE is a novel, differentiated product that improves dialysis maintenance procedure outcomes, as demonstrated in the compelling body of clinical evidence evaluating safety and efficacy to date. And we offer unique size offerings with our 14 and 16 millimeter diameter devices that represent potential treatment options for clinicians previously not available in the marketplace. The data suggests that the Rap City CIE requires fewer re-interventions to maintain patency at the lesion site, and more importantly, that the access circuit remains functional, which is key for any dialysis patient. We believe the Rap City CIE offers a compelling opportunity to not only improve patient outcomes but also to reduce the cost of treating this patient population.

We believe the rapidly CIE is a completely new treatment option for patients, as evidenced by our breakthrough designation from the FDA.

The rapidity cie is a novel differentiated product that improves dialysis maintenance procedure outcomes as demonstrated in the compelling body of clinical evidence, evaluating safety and efficacy to date. And we offer unique size offerings with our 1416. Mm diameter devices that represent potential treatment options for clinicians previously not available in the marketplace.

the data suggests that the rap city cie requires fewer reinventions to maintain patency at the lesion site and more importantly that the accent circuit remains functional

Which is key for any dialysis patient.

Fred Lampropoulos: These factors, together with demonstrated clinical outcomes and the fact that the Rap City CIE is the only device that has been designed specifically for dialysis access maintenance, support our belief that the Rap City CIE is a premium product in the market. Our US commercial and pricing strategy was designed to maximize the compelling long-term opportunity for the Rap City CIE in the US market, and importantly, these strategies were aligned with our efforts to secure reimbursement coverage and payment as well. As discussed on prior calls, our reimbursement strategy is focused on securing add-on payment for procedures completed in both inpatient and outpatient sites of care. For the inpatient setting, our efforts to secure add-on payment remain on track.

We believe the rapsy CIA offers a compelling opportunity to not only improve patient outcomes, but also to reduce the cost of treating this patient population.

These factors together with demonstrated clinical outcomes and the fact that the rapsy cie is the only device that has been designed specifically for dialysis access maintenance.

Supports our belief that the rapsy cie is a premium product in the market.

Our us commercial and pricing. Strategy was designed to maximize the compelling long-term opportunity for the rapsy cie in the US market. And importantly, these strategies were aligned with our efforts to secure reimbursement, coverage, and payment as well.

Fred Lampropoulos: On April 11th, CMS released proposed fiscal year '26 payment rates for the hospital inpatient prospective payment system, which included CMS proposal to approve the Rap City CIE for new technology add-on payment, or NTAP, for the fiscal year 2026. CMS proposed that the maximum new technology add-on payment for a case involving the use of the Merit Rap City CIE would be $3,770 for fiscal year 2026, which, if finalized as proposed, would support our anticipated cost to the hospital, inclusive of all components and accessories, of $5,800. We understand that the effective date for this NTAP add-on payment is anticipated to be October 1st, 2025, for CMS 2026 inpatient fiscal year. With respect to our progress towards securing add-on payment for procedures in the outpatient setting, candidly, a full sum update requires additional discussion and clarification.

For the inpatient setting. Our efforts to secure add-on payment, remain on track.

On April 11th, CMS release proposed fiscal year. 26, payment rates for the hospital, inpatient prospective payment system which included CMS proposal to approve, the wraps, City cie for new technology, add-on payment, or end tap, for the fiscal year 2026.

CMS proposed that the maximum new technology add-on payment for a case, involving the use of the Merit Rap City cie would be 37770 for fiscal year 2026.

which if finalized as proposed would support our anticipated cost to the hospital, inclusive of all components and accessories of 5,800

We understand that the effective date for this endap add-on. Payment is anticipated to be October 1st 2025, for CMS 2026, inpatient, fiscal year.

Fred Lampropoulos: First, and for the avoidance of doubt, our strategy for securing reimbursement for Rap City CIE procedures outside the hospital inpatient setting is not changed. However, we would like to clarify the terminology we have used in the past to describe our strategy for this portion of the market. Our strategy has been focused on the hospital outpatient, or HOPD, setting instead of the office-based lab or OBL setting, as we have previously referenced. The outpatient setting represents a significant portion of the initial addressable market opportunity in the US for the Rap City CIE. According to Clarivate's Dialysis Access Treatment Devices Market Insights US report published in September 2024, there were 95,000 stent units implanted for dialysis access maintenance in 2023. Approximately 79% were implanted in non-hospital sites of care, the majority of which were in the outpatient setting.

With respect to our progress towards securing add-on payment for procedures in the outpatient setting, candidly, a wholesome update requires additional discussion and clarification.

first, and for the avoidance of doubt,

Our strategy for secure reimbursement, perhaps the CIE procedures outside the hospital. The inpatient setting is not changed.

However, we would like to clarify the terminology. We have used in the past to describe our strategy for this portion of the market.

Our strategy has been focused on the out-of-hospital outpatient (HOPD) setting instead of the office-based lab (OBL) setting, as we have previously referenced.

The outpatient setting represents a significant portion of the initial addressable Market opportunity in the US for the rap city cie according to Clare of hates dialysis access treatment devices Market insights us report. Published in September 2024. There were 95,000 stent units, implanted for dialysis access maintenance in 2023,

Fred Lampropoulos: We would also like to clarify a point concerning our application for reimbursement for Rap City CIE in the US HOPD setting. In late February, we submitted an application for new technology ambulatory payment classification, or APC, assignment under the hospital outpatient prospective payment system, or OPS. This was the first time Merit pursued reimbursement for a PMA product, and we engaged external advisors to assist in that process. Our external advisors filed an application to secure an APC assignment and confirmed filing prior to the deadline. Unfortunately, our team believed that the application filed was for the transitional pass-through, or TPT, add-on payment. Our internal discussion and references to this portion of our US strategy, as well as our public commentary, reflected this misunderstanding.

Approximately 79% were implanted in nonh hospital. Sites of care. The majority of which were in the outpatient setting.

We would also like to clarify a point, concerning our application for reimbursement. Perhaps the cie in the US hopd setting.

In late February, we submitted an application for new technology ambulatory payment classification, or APC, assignment under the hospital outpatient prospective payment system, or OPPS.

This was the first time.

Merit pursued reimbursement for a PMA product and we engaged external advisors to assist in that process.

Our external advisors filed an application to secure an APC assignment and confirmed filing prior to the deadline.

Fred Lampropoulos: Rap City CIE was not awarded a new technology APC assignment as part of the calendar year 2026 OPS and Ambulatory Surgical Center proposed rule published on July 15th, 2025. We are executing on a strategy to respond to CMS's determination on the Rap City CIE APC assignment. We have engaged with CMS in recent weeks to understand why we were not awarded a new APC assignment for 2026. While the review of our application has been completed by CMS, we are utilizing the 60-day comment period to provide further supporting evidence, which CMS will review. The deadline for submission of additional information is September 15th. We believe we will hear CMS's final decision on this application as part of the calendar year 2026 OPS and Ambulatory Surgical Center final rule, which is expected to be published in November.

Unfortunately our team believed that the application filed was for the transitional pass through or TPT at on payment our internal discussion and references to this portion of our us strategy as well as our public commentary reflected. This misunderstanding

Wrap City c. I e was not awarded a new technology APC assignment.

As part of the calendar year 2026, the Ops and Ambulatory Surgical Center proposed rule was published on July 15, 2025.

We are executing on a strategy to respond to cms's, determination on the rap city cie, APC assignment.

We have engaged with CMS in recent weeks to understand why we were not awarded a new APC assignment for 2026.

Rather the review of our application has been completed by CMS, we are utilizing the 60-day common period to provide further supporting evidence, which CMS will review.

The deadline for submission of additional information is September 15th.

iCal Center, final rule, which is um, expected

Fred Lampropoulos: We appreciate the discussions with CMS in recent weeks, and we believe we have a solid plan for utilizing the comment period to enhance our case that Rap City CIE meets the requirements for an APC assignment. Separately, we are preparing our application for TPT add-on payment under Medicare's OPS system. We are targeting submission of our application by September 1, 2025, deadline, and anticipate receiving a decision with respect to the award of TPT add-on payment for procedures in the outpatient setting in December 2025. With all of that said, I want to reiterate that our reimbursement strategy for the outpatient setting has not changed. However, Raul and I are disappointed. Our intention with respect to all of our US Rap City messaging was to be transparent with the investment community regarding the key milestones related to our reimbursement strategy following PMA approval.

Um, to be published in November.

We appreciate the discussions with CMS in recent weeks and we believe, we have a solid plan for utilizing the common period to enhance our case. That wraps the cie meets the requirements for an APC assignment.

Separately, we are preparing our application for TPP add-on payment under medicare's op system.

We are targeting submission of our application, by September 1 2025.

Um uh deadlines and anticipate receiving a decision. With respect to the award of TPT add-on payment for procedures in the outpatient setting in December 2025.

With all of that said,

Fred Lampropoulos: We did not communicate the strategy effectively. We are correcting our mistake this afternoon, and we are focused on executing the strategy for this significant portion of the US market. Clearly, we all have a better understanding of the process and terminology from this experience. Importantly, we recognize that this represents a two-quarter delay in expected timing for securing add-on reimbursement in the outpatient setting. We have not changed our expectations for the long-term addressable market in the US for Rap City CIE growth or the potential contributions to our long-term growth profile as we commercialize this technology in years to come. With that said, let me turn the time over to Raul now for an in-depth review of our quarterly financial results and our updated financial guidance for 2025.

I want to reiterate that our reimbursement strategy for the outpatient setting has not changed however Raul and I are disappointed. Our intention with respect to all of our us. Rapsy messaging was to be transparent, uh, with the investment Community. Regarding the key Milestones related to our reimbursement strategy following PMA approval.

We did not communicate the strategy effectively.

We are correcting our mistake this afternoon and we are focused on executing the strategy for the significant portion of the US market. Clearly we all have a better understanding of the process and terminology from this experience. Importantly, we recognize that this re represents a 2 quarter delay in expected timing for securing add-on reimbursement, in the outpatient setting.

We have not changed our expectations for the long term addressable Market in the US, uh, for, uh, wrap City, CIA growth or the potential contributions to our long-term growth profile. As we commercialize this technology in years to come,

with that said,

Raul Parra: Raul, thank you, Fred. I will start with a detailed review of our revenue results in the second quarter, beginning with the sales performance in each of our primary reportable product categories. Note, unless otherwise stated, all growth rates are approximated and presented on both a year-over-year and constant currency basis. Second quarter total revenue growth was driven by 10% growth in our cardiovascular segment and 81% growth in our endoscopy segment. Cardiovascular segment sales exceeded the high end of the expectations we outlined on our first quarter call, and endoscopy sales came in at the high end of our expectations. Our total revenue results included approximately 19.6 million of revenue from our acquisitions of the lead management product portfolio from Cook Medical, the assets of Endogastric Solutions, and to a lesser extent, the acquisition of BioLife following the May 20th closing.

Let me turn the time over to Rahul now for an in-depth review of our quarterly financial results and our updated financial guidance for 2025.

bro.

Thank you Fred. I will start with the detailed review of our Revenue results. In the second quarter beginning with the sales performance in each of our primary reportable product categories.

Note: unless otherwise stated, all growth rates are approximated and presented on both a year-over-year and constant currency basis.

Second quarter total revenue growth was driven by 10% growth. In our cardiovascular statement and 81% growth in our endoscopy segments.

Cardiovascular SE segment sales, exceeded the high-end of the expectations, we outlined on our first quarter, call and endoscopy sales came in at the high end of our expectations.

Our total revenue results included approximately 19.6 million of revenue. From our Acquisitions of the lead management product portfolio from cook medical the assets of Lindo. Gastric Solutions,

Raul Parra: Excluding sales of acquired products, segment revenue growth on an organic constant currency basis was 6.8% for our cardiovascular segment and 1% for our endoscopy segment. Turning to a review of our second quarter revenue results by product category, cardiac intervention product sales increased 23% and represented the largest driver of cardiovascular segment growth in the period. Excluding the contributions from the sale of acquired products, cardiac intervention product sales increased approximately 10% on an organic constant currency basis, well above the high end of organic growth expectations we assumed for Q2. Rounding out the Q2 performance across the rest of our cardio segment, sales of our peripheral intervention products and our custom procedure solutions products increased 6%, which was in line and above the high end of our expectations, respectively. Sales of our OEM products increased 4% in Q2, modestly lower than our expectations.

And to a lesser extent, the acquisition of BioLife following the May 20th closing.

Excluding sales of acquired products segment, Revenue growth on an organic constant currency basis was 6.8% for our cardiovascular segment and 1% for our endoscopy segment.

Turning to a review of our second quarter, revenue results by product category.

Cardiac intervention product sales increased 23% and represented the largest driver of cardiovascular segment growth in the period.

Excluding the contributions from the sale of acquired products. Cardiac intervention product sales increased approximately 10% on. An organic constant currency basis.

Well, above the high end of organic growth expectations. We assumed for Q2,

Rounding out the Q2 performance across the rest of our cardio segment, sales of our peripheral intervention products.

And our custom procedure Solutions products increased 6%.

Which was in line.

And above the high end of our expectations respectively.

Raul Parra: The softer than expected OEM performance in Q2 was entirely related to sales to OEM customers outside the US, which continues to see demand trends impacted by the macro environment. Sales to OEM US customers increased in the high teens year-over-year in Q2. Turning to a brief summary of our sales performance on a geographic basis, our second quarter sales in the US increased 17% on a constant currency basis and 10% on an organic constant currency basis, exceeding the high end of our organic growth expectations by 230 basis points. We were pleased to see continued strong demand from our US customers in the second quarter. International sales increased 7% year-over-year and increased 2% on an organic constant currency basis. Sales results in APAC exceeded our expectations.

Sales of our OEM products increase 4% in Q2 modestly, lower than our expectations.

The softer than expected OEM performance in Q2 was entirely related to sales to OEM customers outside the US.

Which continues to see demand Trends impacted by the macro environment?

Sales to O, OEM us customers increase in the High Teens year-over-year since YouTube.

Turning to a brief summary of our sales performance, on a geographic basis.

In the US, increased 17% on a constant currency basis and 10% on. An organic, constant currency basis exceeding. The high end of our organic growth, Expectations by 200 B 230 basis points.

We were pleased to see continued strong demand from our U.S. customers in the second quarter.

International sales increased 7% year-over-year and increased 2% on an organic constant currency basis.

Raul Parra: EMEA was in line, and sales results in the rest of the world were slightly below the expectations supporting our Q2 guidance range. With respect to China specifically, sales decreased 6% compared to a low single-digit growth rate assumed in our guidance. We attribute the softness to the broader macro environment as the BVP impact was essentially in line with expectations in Q2. Turning to a review of our P&L performance, for the avoidance of doubt, unless otherwise noted, my commentary will focus on the company's non-GAAP results during the second quarter of 2025, and all growth rates are approximated and presented on a year-over-year basis. We have included reconciliations from our GAAP reported results to the related non-GAAP items in our press release and presentation available on our website. Gross profit increased approximately 17% in the second quarter. Our gross margin was 53.2%, up 167 basis points.

Sales results in a pack. Exceeded our expectations.

EMA was in line, and sales results in the rest of the world were slightly below their expectations, supporting our Q2 guidance range.

With respect to China specifically, sales decreased 6%, compared to a low single-digit growth rate assumed in our guidance.

The attribute, the softness to the broader macro environment as the bvp impact was essentially in line with the expectations in Q2.

Turning to a review of our P&L performance for the avoidance of doubt. Unless otherwise noted, my commentary will focus on the company's non-GAAP results. During the second quarter of 2025, all growth rates are approximated and presented on a year-over-year basis.

We have included reconciliations from our Gap, reported results to the related non-gaap items. In our press release and presentation available on our website.

Gross profit increased approximately 17% in the second quarter.

Raul Parra: Approximately half of the increase in gross margin was driven by lower tariff impact versus what our guidance contemplated, with the balance coming from favorable product, geographic revenue mix, and improvements in pricing. Operating expenses increased 15%. The increase in operating expenses was driven by a 13% increase in SG&A expense and a 24% increase in R&D expense compared to the prior year period. Total operating income in the second quarter increased 13.1 million, or 19%, to 80.9 million. Our operating margin was 21.2% compared to 20.1% in the prior year period, an increase of 109 basis points year-over-year. Second quarter other expense net was 2.3 million compared to income of 1.4 million last year. The change in other expense net was driven by lower interest income associated with lower cash balances, offset partially by lower interest expense compared to the prior year period.

Our gross margin was 53.2%, up 167 basis points. Approximately half of the increase in gross margin was driven by lower tariff impact versus what our guidance contemplated, with the balance coming from favorable product, geographic revenue mix, and improvements in pricing.

Operating expenses increased 15%. The increase in operating expenses was driven by a 13% increase in SG&A expense and a 24% increase in R&D expense compared to the prior year period.

Total operating income in the second quarter, increased 13.1 million or 19% to 80.9 million.

Our operating margin was 21.2%, compared to 20.1% in the prior year period, an increase of 109 basis points year-over-year.

Is 2.3 million compared to income of 1.4 Million last year.

Raul Parra: Second quarter net income was 61 million, or $1.01 per share, compared to 53.8 million, or 92 cents per share in the prior year period. We are pleased with our profitability performance in the second quarter, where we leveraged stronger than expected revenue results to drive significant expansion in operating margin and strong growth in non-GAAP diluted earnings per share, both of which exceeded the high end of our expectations. Note, our second quarter non-GAAP EPS results included incremental dilution related to our convertible debt that represented approximately 1 cent to Q2 EPS. Turning to a review of our balance sheet and financial condition, we generated 70 million of free cash flow in the second quarter of 2025, up 20% year-over-year.

The change in other expense, net was driven by lower interest income associated with lower cash balances, offset partially by lower interest expense compared to the prior-year period.

Second quarter. Net income was 61 million or $1.01 per share compared to 5853.8 million or 92 cents per share in the prior year period.

We are pleased with our profitability performance in the second quarter where we leveraged stronger than expected Revenue results to drive significant expansion in operating margin and strong growth in non-gaap diluted earnings per share.

Both of which exceeded the high end of our expectations.

No, our second quarter, non-gaap EPS results included. An incremental, dilution related to our convertible debt that represented proxy 1 cent to Q2 Epps.

Raul Parra: As of June 30th, 2025, Merit had cash and cash equivalents of 341.8 million, total debt obligations of 747.5 million, an outstanding letter of credit guarantees of 2.9 million, with additional available borrowing capacity of approximately 697 million compared to cash and cash equivalents of 376.7 million. Total debt obligations are 747.5 million, an outstanding letter of credit guarantees of 2.9 million, with additional available borrowing capacity of approximately 697 million as of December 31st, 2024. Our net leverage ratio as of June 30th was 1.7 times on an adjusted basis. Turning to a review of our fiscal year 2025 financial guidance, which we updated in today's press release.

Turning to a review of our balance sheet and financial condition, we generated 70 million of free cash flow in the second quarter of 2025 up. 20% year-over-year.

As of June 30th, 2025 Merit had cash and cash equivalents of 341.8 million.

Total debt obligations of 747.5 million.

And outstanding letter of credit guarantees of 2.9 Million.

With additional available bar and capacity of approximately $697 million.

Compared to cash and cash equivalents of 376.7 million.

Total debt obligations are $747.5 million.

And now it's sending a letter of credit guarantees of 2.9 Million.

With additional available borrowing capacity of approximately 697 million as of December, 31st 2024.

Our net leverage ratio as of June 30th was 1.7 times on an adjusted basis.

Raul Parra: For reference, we have included a table in our earnings press release, which details each of our formal financial guidance ranges and how those ranges are compared to our updated guidance ranges issued as part of our press release on May 20th, 2025. Our updated 2025 guidance assumes the following: GAAP net revenue growth of 10% to 11% year-over-year, which we expect to result from net revenue growth of approximately 9% to 10% in our cardiovascular segment, and net revenue growth of approximately 32% to 34% in our endoscopy segment, and a tailwind from changes in foreign currency exchange rates of approximately 6.2 million, or approximately 46 basis points to growth year-over-year. Excluding the impact of changes in foreign currency exchange rates, we expect total net revenue growth on a constant currency basis in a range of 9.7% to 10.6% in 2025.

Turning to a review of our fiscal year 2025 Financial guidance which we updated in today's press release.

For reference, we have included a table in our earnings press release which details each of our formal Financial guidance ranges and how those ranges compared to our updated guidance. Ranges issued as part of our press release on May 20th 2025.

our updated 2025 guidance assumes the following,

6.2 million or approximately 46 basis points to growth year-over-year?

Raul Parra: Among other factors to consider when evaluating our projected constant currency revenue growth range for 2025 are the following items. First, the midpoint of our total constant currency growth range now assumes 12% growth in the US and 8% growth outside the US. The 8% constant currency growth we expect outside the US continues to assume low double-digit growth in EMEA, mid-teens growth in the rest of the world region, and approximately 2% growth in the APAC region. Second, our total net revenue guidance for fiscal year 2025 also assumes inorganic revenue contributions from the business and assets acquired from Endogastric Solutions, Cook Medical, and BioLife on July 1st, 2024, November 1st, 2024, and May 20th, 2025, respectively, in the range of 56 to 58 million in the aggregate.

In the impact of changes in foreign currency exchange rates. We expect total net revenue growth on a constant currency basis in a range of 9.7% to 10.6% in 2025,

among other factors to consider when evaluating our projected constant currency Revenue growth,

Range for 2025 are the following items.

First, the midpoint of our total cost currency growth range now assumes 12% growth in the U.S. and 8% growth outside the U.S.

The 8% constant currency growth. We expect outside the U.S. to continue to assume low double-digit growth in the MEA.

Mid teens growth and rest of the world region and approximately 2% growth in the APAC region.

Raul Parra: Excluding this inorganic revenue, our guidance reflects total net revenue growth on a constant currency organic basis in the range of approximately 5.6% to 6.4% year-over-year. Third, for the full year 2025 period, we now forecast US revenue from the sales of Rap City CIE in the range of 2 million to 4 million. This updated range reflects the impact of our revised timing for securing add-on reimbursement in the outpatient setting. Our prior guidance range assumed the third and fourth quarters of 2025 would see strong customer adoption and utilization trends as a result of the incremental add-on reimbursement and improving procedure economics. Per CMS guidelines, applications for TPT add-on reimbursement submitted by the next deadline of September 1st, 2025, if awarded, will be eligible for use beginning January 1st, 2026.

Second, our total net revenue guidance for fiscal year, 2025 also assumes inorganic Revenue contributions from the business and assets acquired from endogastric Solutions cook medical and BioLife on July 1st 2024. November 1st 2024, and may 2020 2025 respectively in the range of 56 to 58 million in the aggregate.

Excluding this inorganic Revenue, our guidance reflects total, net revenue growth on a cost, concurrency organic basis in the range of approximately 5.6% to 6.4% year-over-year.

For the full year 2025 period. We now forecast us revenue from the sales of rap city cie in the range of 2 million to 4 million.

This updated range reflects the impact of our revised timing for securing add-on rears and bent in the outpatient setting.

Our prior guidance range assumed the third and fourth quarters of 2025 would see strong customer adoption.

And utilization trends, as a result of the incremental add-on reimbursement, are improving procedure economy and economics.

Raul Parra: With respect to profitability guidance for 2025, we now expect non-GAAP diluted earnings per share in the range of $3.52 to $3.72 compared to our prior guidance range of $3.28 to $3.41. The change in our non-GAAP EPS expectations for 2025 reflects the flow-through of the better-than-expected financial performance over the first half of 2025 at both the low and high ends of the non-GAAP EPS range, specifically 35 cents and 21 cents, respectively. The low and high ends of the updated non-GAAP EPS range also reflect the impact of higher interest expense and a higher non-GAAP tax rate assumption, representing the offsets to the aforementioned first half '25 EPS flow-through of 4 and 7 cents, respectively. The high end of non-GAAP EPS range also includes our updated projected impact of tariffs, trade policies, and related actions recently implemented by the US and other countries.

For CMS guidelines applications for TPT add-on reimbursement. Submitted by the next deadline of September 1st 2025, if awarded will be eligible for use beginning, January, 1st 2026,

With respect to profitability guidance for 2025, we now expect non-GAAP diluted earnings per share in the range of $3.52 to $3.72, compared to our prior guidance range of $3.28 to $3.41.

The change in our non-gaap EPS, expectations, for 2025, reflects the flow through of the better than expected financial performance over their first half of 2025.

At both the low and high ends of the non-GAAP EPS range, specifically $0.35 and $0.21 respectively.

The low and high ends of the updated non-GAAP EPS range also reflect the impact of higher interest expense and a higher non-GAAP tax rate, assumptions representing the offsets to the aforementioned first half 25 EPS flow-through of $0.04 and $0.07, respectively.

Raul Parra: Specifically, the high end of our updated guidance range assumes tariff-related manufacturing costs in our total cost of goods line of approximately 7 million compared to 26.3 million previously. Importantly, the 7 million figure is based on available information as of July 30th, 2025, and does not include any impact from new and/or additional tariffs or retaliatory actions or changes to currently announced tariffs, which could change the anticipated impact to our non-GAAP EPS in 2025. The ultimate impact from new and/or additional tariffs or retaliatory actions or changes to currently announced tariffs on our business will depend on the timing, amount, scope, and nature of such tariffs, among other factors, most of which are currently unknown. The tariff situation and potential retaliatory measures by other countries remain highly uncertain and dynamic.

The high end of non-gaap eps range. Also includes our updated. Projected impact of tariffs trade policies, and related actions recently implemented by the Us and other countries.

Specifically, the high end of our updated guidance range, as soon as tariff related manufacturing costs in our total cost of this line of approximately 7 million compared to 26.3% previously.

Importantly, the 7 million figure is based on available information as of July 30, 2025, and does not include any impact from new and/or additional tariffs or retaliatory actions, or changes to currently announced tariffs, which could change the anticipated impact to our non-GAAP EPS in 2025.

The ultimate impact from new Andor additional tariffs, or retaliatory, actions or changes to currently announced tariffs on our business will depend on the timing amount scope and nature of such tariffs among other factors most of which are currently unknown.

Raul Parra: As such, the low end of our EPS range continues to reflect a tariff-related impact on our 2025 cost of goods of 26.3 million. Returning to a discussion of our updated 2025 financial guidance assumptions for modeling purposes, our fiscal year 2025 financial guidance now assumes non-GAAP operating margins in the range of approximately 19% to 20% compared to 17.6% to 18% previously. Note, the change in our 2025 non-GAAP operating margin expectations is primarily attributed to lower expected impact from tariffs and, to a lesser extent, the flow-through of stronger than expected financial performance in the first half of 2025. Non-GAAP interest and other expense net of approximately 8 million compared to 4.8 million previously. Non-GAAP tax rate of approximately 22.5% compared to 21% previously, and diluted shares outstanding of approximately 61 million.

The tariff situation and potential retaliatory measures by other countries remain highly uncertain and dynamic. As such, the low end of our EPS range continues to reflect a tariff-related impact on our 2025 cost of goods of $26.3 million.

Returning to our updated 2025 financial guidance assumptions for modeling purposes. Our fiscal year 2025 financial guidance now assumes non-GAAP operating margins in the range of approximately 19% to 20%, compared to 17.6% to 18% previously.

Note the change in our 2025 non-gaap operating margin. Expectations is primarily attributed to lower expected impact from tariffs. And to a lesser extent, the flow through of stronger than expected financial performance. In the first half of 2025.

Non-GAAP interest and other expense, net of approximately $8 million, compared to $4.8 million previously.

Non-gaap tax rate of approximately 22.5% compared to 21% previously.

Raul Parra: Note, our weighted average share count assumption continues to reflect incremental dilution of approximately 0.9 million shares related to our convertible debt facility. We continue to estimate incremental share dilution related to our convertible debt facility represents an impact of approximately 5 cents to our non-GAAP EPS in 2025. Finally, we continue to expect to generate free cash flow of at least 150 million in 2025, inclusive of the expectation that we invest approximately 90 to 100 million in capital expenditures this year. We would also like to provide additional transparency related to our growth and profitability expectations for the third quarter of 2025. Specifically, we expect our total revenue to increase in the range of approximately 8.6% to 10.5% on a GAAP basis and up approximately 8% to 9.8% on a constant currency basis.

Diluted shares outstanding of approximately 61 million.

Note our weighted average share. Countless

assumption can use to reflect incremental dilution of approximately 0.9 million shares related to our convertible debt facility.

We continue to estimate incremental, shared douching related to our convertible debt. This facility represents an impact of approximately $0.05 to our non-GAAP EPS in 2025.

Finally, we continue to expect to generate free cash flow of at least 150 million in 2025 inclusive of the expectation. That we invest approximately 90 to 100 million in capital expenditures, this year,

We would also like to provide additional transparency related to our growth and profitability expectations for the third quarter of 2025.

Raul Parra: The midpoint of our third quarter constant currency sales growth expectations assumes approximately 7% growth in the US and 11% growth in international markets. Note, our third quarter constant currency sales growth expectations include inorganic revenue in the range of 13.3 million to 14.3 million. Excluding inorganic contributions, our third quarter total revenue is expected to increase in the range of approximately 4% to 5.6% on an organic constant currency basis. With respect to our profitability expectations for the third quarter of 2025, we expect non-GAAP operating margins in the range of approximately 16.9% to 18.5% compared to 19.2% last year, and non-GAAP EPS in the range of 76 cents to 85 cents compared to 86 cents last year. That wraps up our prepared remarks, operator. We would now like to open up the line for questions.

Specifically. We expect our total revenue to increase in the range of approximately 8.6 to 10.5% on a gap basis and not approximately 8 to 9.8% on a constant currency basis.

The midpoint of our third quarter constant currency sales growth expectations is approximately 7% growth in the US.

And 11% growth in international markets.

No, our third quarter constant currency sales, growth expectations, include inorganic Revenue in the range of 13.3 million, to 14.3 million. Excluding inorganic contributions, our third quarter, total revenue is expected to increase in the range of approximately 4 to 5.6%, on an organic constant currency basis.

With respect to our profitability, expectations, for the third quarter of 2025, we expect non-gaap operating margins in the range of approximately 16.9 to 18.5% compared to 19.2% last year.

And non-GAAP UPS is in the range of $0.76 to $0.85, compared to $0.86 last year.

Operator: Thank you. If you would like to ask a question, please press star one one on your telephone. You will then hear an automated message advising your hand is raised. If you would like to remove yourself from the queue, press star one one again. We ask that you please wait for your name and company to be announced before proceeding with your question. One moment while we compile the Q&A roster. The first question that I have for today will be coming from the line of Jason Bedner of Piper Sandler. Your line is open.

That wraps up our prepared remarks operator. We would now like to open up the line for questions.

Thank you. If you would like to ask a question, please press star, 1 1, 1 on your telephone, you will then hear an automated message. Advising. Your hand is raised. If you would like to remove yourself from the queue press star on 1. Again, we ask that you please wait for your name and Company to be announced before proceeding with your questions 1 moment while we compile the Q&A roster.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Afternoon, good. Congrats on another nice quarter with the P&L here. I'll kick things off on Rap City, and I'll just preface this by saying I'm sorry for any confusion. It's just a busy afternoon here and bouncing between a few calls, but I'm not receiving TPT. And maybe just lay it out. Was there, I guess, was there a problem with the actual filing or, and sorry, just with trying to read through the script, it was not necessarily clear to me. Did you receive feedback from CMS? You know, maybe talk about your engagement with CMS since. I think a lot of investors are trying to handicap the likelihood of receiving TPT under the new December timeline. So maybe you can clarify and just, you know, what gives you confidence in this new timeline.

The first question that I have for today, will be coming from the line of Jason bnar of Piper Sandler. Your line is open.

Fred Lampropoulos: Yeah, Jason, this is Fred. Let me walk through the Rap City fact-based story so that you can hear this all in sequence. Again, we provided an update on US reimbursement in an outpatient setting. We applied for new technology APC assignment by the 3/1 deadline. CMS did not award a new APC assignment as part of the proposed rule on 7/15. Now that the application for the new APC assignment is completed, you know, we intend to submit an application for transitional pass-through or TPT. The deadline for that submission is 9/1, and if awarded, it'll become effective January 1st of 2026.

Afternoon guys. Uh, congrats on another nice quarter with the p&l here. Um, I'll I'll kick things off on Rap City and I'll just preface this by saying I'm sorry for any confusion. It's just, it's a busy afternoon here and bouncing between a few calls. But I'm, I'm not receiving TPT, and may maybe just lay it out, was there, I guess was there a problem with the actual filing or, and sorry, just with with, with trying to read through the script? It was, it was not necessarily clear to me. Did you receive feedback from CMS? Um, you know, I mean maybe talk about your engagement with CMS since I think a lot of investors are trying to handicap the likelihood of receiving TPT under the new December timeline. Uh, so maybe you can clarify and just, you know, what gives you confidence in this new timeline?

Yeah, Jason, this is Fred. Let me walk through the Reps, the fact-based story. So you can hear this all in sequence. Again, we provided an update on reuse reimbursement, um, and an outpatient setting. We applied for new technology. APC assignment by the 31 deadline.

CMS did not award a new APC assignment as part of the proposed rule on 715.

Now that the application for the new APC assignment is completed, you know we intend to submit an application for Transitional Pass-Through or TPT. The deadline for that submission is 91.

Fred Lampropoulos: Revised 2025 revenue expectations for US Rap City due to the six-month delay for potential contributions related to TPT add-on, and we have not, you know, we have not changed any of our expectations for the long-term addressable market in the US for the Rap City CIE or the potential contributions to our long-term growth profile of the company. We corrected our prior commentary on the application for reimbursement in the outpatient setting, and for the avoidance of doubt, our prior commentary regarding our submission for TPT add-on by the March 1st deadline was not correct. We are targeting submission for TPT add-on by September 1st, which is the deadline. So I hope that that brings it and that we, I hope that answers your question.

and if awarded, it'll become effective January 1, 2026,

Revised 2025 revenue expectations for us regarding repsy, due to the 6-month delay for potential contributions related to the TPT add-on.

And we have not, you know, we have not changed any of our expectations for the long-term addressable market in the U.S. for the rapidly CAGR or the potential contributions to our long-term growth profile of the company. We corrected our prior commentary on the application for reimbursement in the outpatient setting. And for the avoidance of doubt,

our prior commentary regarding our submission for TPT add-on by the March 1st deadline was not correct.

Which is the deadline.

So, I hope that brings it, and that we, um,

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Yeah, that's helpful.

Fred Lampropoulos: That's a lot of information.

I hope that answers your question.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Yeah, yeah, no, it's always, you know, fun and complex dealing with reimbursement and some of the different rules and deadlines here. But maybe, Fred, can you, to follow up, can you maybe give investors the confidence or maybe describe what gives you the confidence on hitting that new deadline or, you know, securing, not necessarily hitting the deadline, but securing TPT under the new deadline that you have set or the expectations you've set here? And then, you know, I'm sure you don't want to go there and unpack in all the different possible paths, but maybe you can talk about the commitment you have to securing TPT, you know, against maybe a more aggressive commercial launch without TPT, let's if in the scenario that you don't receive in December.

Yeah, a lot of information.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): I guess I'm just curious how many times you want to go down this road, you know, in going after it. I would think a lot because it's economically attractive, but there's some puts and takes here. So maybe if you can have that discussion as well, it'd be helpful. But just go ahead, Raul.

Raul Parra: Yeah, just to clarify, Jason, I think, you know, essentially what we're saying is we were under the assumption that we had filed for TPT, right? But it had not. So it's not like we're refiling. We went for APC. It was clear that that, you know, that was filed timely. Didn't get the outcome that we wanted, just to be clear. We're engaging with CMS and having those discussions and making sure that we're clear. But we are confident, you know, that we'll meet the deadline for TPT. I would say that nothing has changed. We continue to like our, you know, our expectations for meeting all the TPT guidelines. We think we meet them. Obviously, clearly, we have to submit, and then it's a waiting game. But I think we all around here are encouraged just by the fact that, you know, we have the best data.

Yeah, yeah, I know it's always always, uh, you know, fun and complex deal with reimbursement and, and the, the some of the different rules and deadlines here, but maybe Fred can you to follow up? Can you maybe give investors the confidence? Um, or maybe describe what gives you the confidence on hitting that new deadline or, you know, securing uh not necessarily hitting the deadline but securing TBT. Uh, under the new deadlines that you have set or the expectations you've set here. Um, and then, you know, I'm, I'm sure you don't want to go there and unpacking all the different possible paths, but maybe you can talk about the commitment you have to securing TPT, um, you know, against maybe a more aggressive commercial launch without TPT, let's if in near the scenario that you don't receive in December. I guess, I'm just curious how many times you want to go down this road. Um, you know, and, and going after it, I would think a lot because the, it's an economically attractive, but there's there's some puts and takes here, so maybe you can have that discussion as well, and be helpful.

But just go ahead. Roll. Yeah, just just to clarify Jason. I I think um, you know

Essentially, what we're saying is we were under the assumption that we had filed for TPT, right? But it had not.

So it's it's it's not like we're refiling we we went for APC. Um it was clear that that you know that was filed Timely.

um,

Didn't get the outcome that we wanted, um, just to be, just to be clear. Uh, we're engaging with CMS. Um, and and having those discussions and and and making sure that we're clear. Um, but we are, we are, uh,

we, we are confident, you know, that we'll, we'll meet the, the deadline for, for TPT, um,

Raul Parra: We've got a great product, and we know we'll do what we thought we were going to do and submit the application by its deadline.

Fred Lampropoulos: So, Jason, you know, this was the first time that Merit pursued reimbursement for a PMA product, and I think you said that it's complicated. And we engaged, you know, external advisors to assist. Our external advisors filed an application on the APC assignment and confirmed filing. So, unfortunately, our team believed that the application filed for TPT add-on payment was the APC. That's how we understood it, and we own it. Our internal discussion referenced to, you know, our strategy as well as our public comments reflected this, you know, the misunderstanding. We expected to receive a response on the application on the proposed rule for 2026 issued on the 15th of July. And as we pointed out, CMS did not award an APC assignment as part of the proposed rule.

I I I would say that nothing has changed. We we, we continue to like our, um, you know, um, our expectations for, for, for meeting all the TPT guidelines. We, we think, uh, we think we meet them, obviously. Clearly we have to submit, um, and, um, and then we'll, then it's a waiting game and, um, but I, I think we, we all around here, um, are encouraged. Um, just by the fact that, you know, we have the best data. We've got a great product, um, and we know what we'll, we'll do what we. We thought we were going to do and and, and re, you know, and and submit the application by its deadline. So Jason, you know, this was the first time that Meritt pursued reimbursement for a PMA product and I think you said that it's complicated and

And we engaged, you know, external advisors to assist our external advisors filed an application on the APC assignment and confirmed filing.

Fred Lampropoulos: And now that that application is complete, we intend to submit an application for the TPT, as I mentioned and Raul mentioned, on 9/1, which is essentially 30 days from now.

So unfortunately our team believed that the application filed for TPT add-on payment um was the APC, that's how we understood it, and we own it, our internal discussion reference to the, you know, to our strategy as well as our public conference, you know, comments reflected this much, you know, the misunderstanding we expected to receive a response, um, on the application on the proposed, rule for 2026 issued on the 15th of July. And as we pointed out, cmsi CMS did not award an APC assignment as part of the proposed rule

and now that that application is complete,

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Yeah. Okay. And I'll let others hop in here, but just to maybe put a bow on it, high confidence on securing TPT later this year.

We intend to submit an application for the TPT, as I mentioned, and Rob mentioned on 91, which is essentially 30 days from now. Yeah.

Fred Lampropoulos: We believe in our product. We believe in the data. We believe that it is the product we think it is. And we believe all of those things, and we have high confidence in that product, yes. And this process, even though we made a mistake, I think we've said that we own it. Nobody else owns it. We own it. And it's going to delay, but that's, I believe, the only thing that's going to delay.

Okay, and I'll, I'll let others hop in here, but just to, to maybe to put a bow on it, eat high confidence on securing TPT later this year. We believe in our product, we believe in the data. We believe that it is, uh, the product. We think it is. And we believe all of those things. And we have high confidence in that product. Yes, and the this process, even though we made a mistake, I think we we've said that we own it. Nobody else owns it. We own it.

Raul Parra: I think, you know, just bottom line, nothing, you know, from a long-term perspective has changed from, you know, our standpoint strategically for this product. And so, you know, the unfortunate part is obviously we thought we had filed the TPT. We got the wording wrong. Obviously, we filed for APC. Now we know where we stand on that, and we move on to the next step, which is TPT, and, you know, have a high level of confidence in the product, Jason.

And if it's going to delay, but that's, I believe, the only thing that's going on. I think, you know, just...

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Understood. Thanks, guys.

Bottom line, nothing, you know, from a long-term perspective has changed from, you know, from our standpoint, uh, strategically for this product. Um, and so I, you know, the unfortunate part is obviously, we thought we had filed a TPT; we got the wording wrong. Obviously, we filed for APC. Now we know where we stand on that, and we move on to the next step, which is TPT, and, you know, have a high level of confidence in the product, Jason.

Fred Lampropoulos: Thank you.Thank

Understood. Thanks guys.

Operator: you. And our next question will be coming from the line of Jason Bedford of Raymond James. Your line is open.

Thank you.

Thank you. And our next question will be coming from the line of Jason Bedford.

Fred Lampropoulos: Hi. Can you hear me, Fred?

Raul Parra: We've got you, Jason.

Fred Lampropoulos: Yeah. I wasn't sure who, who got picked here. So, jeez, I really want to use a three-letter acronym here, but I'm not going to use it. so please don't. Yeah. so I think I understand the difference between APC and TPT. I think a lot has to do with the newness of the technology, but I'd love for you to describe maybe why you're optimistic that you may be able to secure a TPT if you got rejected for an APC, right? So I guess my point is, why would, they not apply the same logic?

Hi, can you hear me, Fred? We've got you, Jason. Yeah, I wasn't sure who got picked here. So, um, geez. I really want to use a 3-letter acronym here, but I'm not going to use it. Um, so please,

Yeah.

so I, I

Raul Parra: Okay. I'm going to pick it up. So this is all, you know, new to us, right? And we're now, now get to be experts in it. But APC is essentially around the procedure, Jason. Correct. Right. And that, that's, that's kind of the distinction where TPC is, is, is cost-based, around the product. Does that help? Does that help, Jason?

Mean APC and TPT uh, I think a lot has to do with the newness of the technology, but I'd love for you to describe maybe why you're optimistic that you may be able to secure a TPT if you got rejected for an APC. Right, so I guess my point is why would um they not apply the same logic, okay I'm gonna let yes pick it up. So this is all you know, new to us. Right? And we're now now get to the expert in it, but APC is essentially around the procedure Jason correct, right. And that that's that's kind of the the distinction where TPC is is, is cost-based um, around the product.

Fred Lampropoulos: It does. and I assume APC kind of lumps you in with everyone else, whereas TPT acknowledges the difference. Is that fair?

Does that help? Does that help? Jason, it does. Um,

Raul Parra: Again, I think what Raul said is procedure-based, and okay, and that was not, they couldn't see the difference. We believed our procedure was different. The CMS believed that there are other, you know, situations like that that are covered, which is why we didn't receive it. TPT acknowledges the differences in the performance of the device, but it's cost-based. Yeah. Does that help? So.

And I assume APC kind of lumps you in with everyone else, whereas TPT acknowledges the difference. Is that fair?

Fred Lampropoulos: And, and, and, yeah. And, and, you know, one of the things that we, you know, we do get a comment period, right? Even though the APC, assignment is complete, we do get to comment, and we, we can, you know, provide additional information as to why we think it's, it's a different procedure. but at the same time, we also know what that outcome is, which means that we can take the, the, the other road, and file for TPT, sorry.

Um, again, I think what Rahul said, it's procedure-based. And, okay. And that was, I'm not, they couldn't see the difference. We believed our procedure was different. The CMS believed that there are other, you know, situations like that that are covered, which is why we didn't receive it. TPT acknowledges the difference is in the performance of the device, but it's cost-based. Yeah.

Does that help? So.

Yeah. And and you know, 1 of the things that we, you know,

We do get a comment period, right? Even though the APC, uh, assignment is complete, uh, we do get to comment and we we can, you know, provide additional information as to why we think it's it's a different procedure. Um, but at the same time we also know what that outcome is which means that we can take the the other Road um and file for TPS.

Raul Parra: Okay. okay. maybe just two, two other quickies. Down 6% in, in, in China, not necessarily, related to VBP. Is there a specific category? Is it competition, or would you chalk it up to just general demand?

TPT sorry, teepee.

Okay, um, okay, uh, maybe just 2 other quickies. Down 6% in China, uh, not necessarily. Um,

Fred Lampropoulos: No, I mean, I think it's just the, the, the current environment, you know, the macro environment, Jason. But I, I think, you know, other than that, there's not much else to see. we, we continue to expect low single-digit growth in APAC for 2025. I don't think, you know, that's changed for us. So, I, I, I'd say it's, it's kind of as expected, quite frankly. You know, that takes some puts, but ultimately, we're kind of where we thought we'd be.

Related to vbp. Is there a specific category? Is it competition? Or would you chalk it up to just general demand?

Raul Parra: Puts and takes of the whole up and down thing. Yeah.

Fred Lampropoulos: Okay. I'll, I'll leave it at that. Thank you.

No, I mean I I think it's just the the, the current environment, you know, the, the macro environment. Um uh Jason. But I I think, you know, uh, other than that there there's not much else to see. Um, we we continue to expect low single digit growth in AP pack for 2025. I don't think, you know that's changed for us. So, um, I I I'd say it's, it's kind of as expected, quite frankly. You know that takes some puts, But ultimately, we're kind of where we thought, we'd be putting takes of the whole up and down thing. Yeah.

Raul Parra: Great. Thank you.

Operator: Thank you. One moment for the next question. And the next question will be coming from the line of Robbie Marcus of JP Morgan. Your line is open.

Okay, I'll I'll leave it at that. Thank you. Great, thank you.

Thank you. 1 moment for the next question.

And the next question will be coming from the line of Robbie Marcos.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Oh, great. congrats on a good quarter. Thanks, for taking the questions. maybe I could start on margins. obviously, a really strong margin upside both on gross and operating margin. Some of it came from less negative tariff impact, but part of it was also underlying. Maybe you could tease out what's what in, gross and operating margin and then walk us through the balance of the year on both.

Oh, JP Morgan. Your line is open.

Oh great. Uh, congrats on a good quarter. Thanks uh, for taking the questions. Um

Maybe I could start on.

Fred Lampropoulos: Yeah. Look, I mean, I think obviously, you know, super proud of the team and of how we're performing. I, I think there's two things that I'd like to highlight. one is obviously our sales force continues to execute at a very high level, you know, with another strong quarter. that obviously helped, you know, from a leverage standpoint on operating expenses and also a gross margin. gross margin, it's, it's a lot of, you know, everything. You know, I think, you know, obsolescence helped us. you know, pricing helped us. our mix has helped us. Again, our sales force, you know, delivering, you know, really good, you know, kind of mix and, and geography mix. Fred.

Margins, uh, obviously a really strong margin upside both on Gross and operating margin. Some of it came from less negative tariff impact, but part of it was also underlying. Maybe you could tease out, what's, what in, uh, gross and operating margin, and then walk us through the balance of the year on both.

Raul Parra: Yeah. And Rob, I was just going to say, I think it has to do with foundations for growth, and it has to do with continued growth initiatives. Those things have not left us. There's still, what we use as alignment for compensation and how we measure ourselves and very candidly how our board measures us. Yeah. So those are, that's part of it too, in that momentum. I also think the, more attention made on, pricing and positioning the product and so on and so forth.

Yeah, look, I mean I think obviously you know super proud of the team of how we're performing. Um I I think there's 2 things that I'd like to highlight. Um 1 is obviously our sales force continues to execute at a very high level, um, you know, with another strong quarter, um, that obviously helped. Um, you know, from a leverage standpoint on operating expenses and also a gross margin, uh, gross margin. Um, it's it's a lot of, you know, everything, you know, I think, you know Ops lessons helped us. Um, you know, pricing helped us. Uh, our mix has helped us again, our sales force, you know, delivering, um, you know, really good, uh, you know, kind of mix and and geography mix.

Fred Lampropoulos: Yeah. Really, the only, you know, kind of, you know, sore spot I would, I would call it is, is the tariffs, which were kind of outside of our control that we had to deal with. you know, so, we ended up with about half of what we anticipated, in the P&L, but we're able to overcome it with strong sales, and obviously the discipline that we showed on, on, on, on pricing and mix.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): And how should we think about, the cadence, particularly on, on gross margin in third, fourth, third quarter, fourth quarter, and the upgrade there? What's, what's less negative tariffs and, and what's underlying?

Attention made on, um, uh, pricing and positioning the product and so on and so forth. Really? The only, you know, kind of, um, you know, uh, sore spot. I would, I would call is, is the terrorists which were kind of outside of our control that we had to deal with, um, you know, so, uh, we ended up with about half of what we anticipated, um, in the p&l. Uh, but we're able to overcome it with strong sales, um, and obviously, the discipline that we showed on, on on, on pricing and mix.

Fred Lampropoulos: You know, I was hoping you're going to forget about that question, Robbie, because, you know, we typically don't guide on gross. Well, actually, we don't guide on gross margin. but I think if you look at the expectations for our operating margin, clearly, we, we took that up. You know, we're in the 19 to 20 percent, you know, range, for the year. clearly, we expect some, you know, a margin to be a, a, a gross margin to be completer. and so I'll just leave it at that, that, you know, we continue to feel, you know, really, you know, good, you know, comfortable with, with our, our guidance for operating margin.

and and how should we think about, um, the Cadence, uh, particularly on on gross margin in third for third quarter, fourth quarter, um, in the upgrade their what, what's, what's less negative tariffs and, and what's underlying

You know, I was hoping you're going to forget about that question Robbie because you know we typically don't guide on girls. Well actually, we don't guide on gross margin, um, but I think if you look at the expectations for our operating margin, uh, clearly we we took that up, you know, we're in the 19 to 20%, you know, range uh, for the year. Uh, clearly we expect some, you know, uh, margin to be a, a, a gross margin to be contributor. Um, and so I I'll just leave it at that. That, you know, we continue to feel, um, you know, really, um,

Fred Lampropoulos: I think we're, you know, as we, as we look to finish up the second year, I think it sets us up really well for, for CGI and what we want to do, you know, for there. I mean, I think if we hit the high end of our guidance, you know, we're already looking at the bottom end of, of CGI, which I think is, is a really good spot to be in.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): You can't blame me for trying, given all the moving parts.

You know, good, you know, comfortable with with our our guidance for operating margin. I think we're, you know, as we as we look to finish up the second year, um, I think it sets us up really well for for CGI and what we want to do, you know, for their I mean I think if we hit the high end of our guidance, um, you know, we're already looking at the bottom end of of CGI which I think is is a really good spot to be in.

Fred Lampropoulos: No, I appreciate it. Yeah. Yeah.

can't blame me for trying, giving all the

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): All right. That's it for me. Thanks a lot.

No, I appreciate it. Yeah, yeah.

Fred Lampropoulos: All right. Thank you.

Raul Parra: Thanks, Robbie.

Operator: Thank you. And the next question will be coming from the line of Steve Litman of Oppenheimer. Your line is open.

All right, that's it for me. Thanks a lot. Thank you. Thanks, Robbie.

Fred Lampropoulos: Thank you. Hi, guys. Wanted to start first with the sales beat in the quarter, particularly around cardiac intervention, which saw a nice uplift, even exceed acquired products. Can you talk a little bit more about what the drivers of that were and, you know, what kind of, sustainability of that growth we could see?

Thank you. And the next question will be coming from the line of Steve. Littman of Oppenheimer. Your line is open.

Raul Parra: Yeah. And let me pick that one up. you know, we generally don't mention names of products, so I won't do that. But I think a lot of this comes out of Merit's products that we have developed internally. I think a lot of it has to do with presence in the lab, and I think the Cook acquisition and the presence in the cardiac area is important. And, and very candidly, we expect that to continue with other products and other things that Merit develops internally. So we think it's going to continue to be one of the strong areas in the company that we focused on. and, it's, a lot of things that other people overlook, and we just don't. Yeah. So that's where we're focused.

Thank you. Uh, hi guys. I wanted to start first with the sales beat in the quarter, particularly around Cardiac Intervention, which saw a nice uplift, even in XC acquired products. Can you talk a little bit more about what the drivers of that were? And, you know, what kind of sustainability of that growth we could see?

Yeah, and let me pick that one up. Um, you know, we generally don't mention names of products, so I won't do that. But I think a lot of this comes out of the marriage products that we have developed internally. I think a lot of it has to do with presence in the lab. And I think the Cook acquisition and the presence in the cardiac area is important. And, um, very candidly, we expect that to continue with the other products and other things that Merit develops internally. So yeah, we think it's going to.

Continue to be one of the strong areas in the company that we focused on. Um, and uh,

Fred Lampropoulos: Add a little more color, right? I, I think, you know, Fred mentioned the the Cook acquisition, which obviously isn't organic yet, but if you remember, one of the reasons we did that acquisition, the strategy behind that was to get deeper into our cardiac, you know, bag and, you know, specifically those products. And, and you see the sales force, you know, focused on them. They're excited about that. And so, you're seeing a little bit of uptick there too.

Raul Parra: There's some pull-through too with the access products that Merit makes. And you got to get in there. And that's kind of our strong suit. Yeah. So that's another part of it as well.

Fred Lampropoulos: Great. Just shifting to margin, obviously, you know, you're benefiting here by being from your conservatism on the first quarter call relative to to tariffs. You know, Raul, you talked at that time about, you know, some work you'd look to do to offset tariffs. How much of that work, you know, can still flow through and maybe drive, you know, excess margin now, even at the lower, hopefully, lower tariff impact?

It. It's um, a lot of things that other people Overlook, and we just don't. Yeah, so that's where we're focused. Add a little more color, right? I I think, you know, Fred mentioned the the cook acquisition which obviously is an organic yet. But if you remember, 1 of the reasons we did that acquisition, um, the strategy behind that was to get deeper into our cardiac, you know, uh, bag and, you know, specifically those products and and you see this sales force, you know, focused on them, they're excited about that. And so, um, you're seeing a little bit of uptick there too. There's some pull through too with the access products that Meritt makes and you got to get in there and that's kind of our strong suit, so that's another part of it as well.

Fred Lampropoulos: Well, you know, I think we're trying to be nimble on some of those things that we're doing, right? I mean, a lot of it was, you know, things that we could do easily, right? Redirect shipments, you know, product line transfers that were already on the books. You know, can we pull those forward? Those are all things that are, that are, that are being worked on. I think, you know, the hard part, quite frankly, is that, it's a fast-moving target that changes almost on a daily basis, right? I think we had two changes just this week. One was confirmed, and one is, you know, was just a rumor out there that, you know.

Great. Um, just shifting to margin, obviously, you know. Um, you’re benefiting here from your conservatism on the first quarter call relative to tariffs. You know, Raul, you talked at that time about, you know, some work you’d look to do to offset tariffs. How much of that work, you know, can still flow through and maybe drive, you know, excess margin now, even at the lower, hopefully, uh, lower tariff impact?

Well, you know, I I, I think we're trying to be nimble on, on some of those things that we're doing, right? I, I mean, a lot of it was, you know, things that we could do easily, write redirect shipments, um, you know, product line transfers that were already on the books, you know, can we pull those forward? Those are all things that are that are, um, that are being worked on. Um, I I think, you know, the hard part quite

Raul Parra: And the president can change his mind. They're going to see what he thinks.

Fred Lampropoulos: Yeah. So, so look, I think that the nice thing, quite frankly, is, you know, just, just being, you know, as transparent as possible on these tariffs. I think our guidance covers a lot, right? I mean, I think when you look at the high end, you know, we've got, you know, roughly $7 million, you know, of, of, you know, impact there. When you look at the low end, we essentially left, you know, that original amount of, you know, $26 million that we had originally called out, in the guidance. So I think we have a, a, you know, a good number in within the range of our guidance to cover all sorts of, you know, changes that may come our way, but it is a moving target. And so, I would just say that we're comfortable where we're at.

Fred Lampropoulos: I think our operations group is doing everything they can to try and and mitigate, you know, the expense, but we're also making sure that they stay focused on what really matters, and that's their CGI targets, which are things that they can control.

Raul Parra: And getting, getting products to our customers.

Fred Lampropoulos: Products to our customers is the key to all of this, no matter what.

Raul Parra: Yeah, yeah.

Fred Lampropoulos: Got it. And then just my one last question on, and on Rhapsody is, what's happening or going to be happening on the ground here as sort of reimbursement work is being done? You know, you obviously, you have an approved product. You have, you know, great data. What's going on in terms of education, training so that when you hopefully get that reimbursement sorted out, kind of hit the ground running?

No, um, that original amount of, you know, 26 million that we had originally called out, um, in the guidance. So I think we have a, a, you know, a good number in within the range of our guidance, to, to cover all sorts of, you know, changes that may come our way. But it is a moving Target. And so, um, I would just say that we're comfortable where we're at, um, I think our operations group is doing everything they can to try and and mitigate, you know, um, the expense. But we're also making sure that they stay focused on what really matters and that's their CGI targets which is things that they can control and getting getting products through our customers products like the key to all of us. No matter what? Yeah. Yeah, yeah.

Raul Parra: Well, listen, I think our updated range assumes that we maintain a premium price. We believe it's a premium product. That has not changed. We do not expect to see a ramp in adoption and utilization in the outpatient setting in the second half, but we do expect to gain market share in the hospital setting where we have approval and where we have, you know, NTAP. So anyway, we have plenty to do. It gives us more time to train, more time to get ready for other expanding markets that, you know, from a regulatory point of view. So, you know, we, you know, this was a punch we took, but it didn't hurt very much. I mean, it hurts. Don't get me wrong, but our eyes are watering, but we're still.

Got it. And then just my 1 last question on and on raps city is, uh, what's happening or going to be happening on the ground here? As sort of reimbursement, work is being done. You know, you obviously you have that approved product, you have, you know, great data, what's going on, in terms of education training. So that when, you know, if we get that reimbursement, uh, sorted out kind of hit the ground running,

Well, yeah, listen, I think our updated range assumes that we maintain a premium price. We believe it's a premium product that has not changed. Um, we do not expect to see a rampant and adoption utilization in the outpatient setting in the second half, but we do expect to gain market. Share in the hospital setting where we have approval and where we have, uh, you know, uh, endap. So, anyway,

Fred Lampropoulos: Yeah, in the fight.

Raul Parra: But we're still in the fight. We're still swinging, so.

Fred Lampropoulos: Got it. Thank you, guys.

Um, we we uh, we have plenty to do, it gives us more time to train, more time to get ready for other expanding markets that you know, from a regulatory point of view. So you know the we uh we got you know, this was a punch, we took, but it didn't hurt very much it. I mean it hurts, don't get me wrong but our eyes are watering but we're still on the fight but we're still in the fight, we're still swinging. So

Raul Parra: Yeah. Thank you.

Got it. Thank you guys.

Operator: Thank you. One moment for the next question. And the next question is coming from the line of Jim Sadodi of Sadodi & Company. Your line is open.

Yeah, thank you.

Thank you. One moment for the next question.

Jim Sidoti: Hi. Good afternoon. Thanks for taking the question. tell me a little bit about BioLife and, and this distribution for Stats. You know, do they have international sales? And is that something you could put through your reps?

And the next question is coming from the line of Jim Sodoi of Saudi and Company. Your line is open.

Raul Parra: Yeah. Part of the attractiveness of this whole deal was they had four distributors in the United States. I can tell you that we've converted all of those and negotiated through all of those, and all of our sales are now coming in direct. So we get orders, and we deliver those directly to customers. On the international side, they're approved, but they didn't have any footprint. We do. So that's always been the attractiveness for us is the growth potential of the product with Merits. And this goes back to the cardiac, and you'll see that fall into line in that part that we were talking about earlier. So it's something, again, I've been watching for 10 years. it's something that our physicians have encouraged us to to look at because they use it. You need to have this.

Hi, good afternoon. Texas taking the question. Um, talk a little bit about BioLife and, um, and this distribution for Statfield. Did they have international sales, and is that something you can put through your reps?

Yeah, part of the attractiveness of this whole deal was they had 4 distributors in the United States. I can tell you that we've converted all of those and negotiated through all of those, and all of our sales are now coming in direct. So we get orders. And we deliver those directly to customers on the international side, they're approved, but they didn't have any footprint. We do, so, that's always been the attractiveness attractiveness for us, is the growth potential of the product with marriage. And this goes back to the cardiac and you'll see that fall into line in that part that we were talking about earlier. So if

Raul Parra: And finally, the right time came up, and away we go. We feel very good about the product. But maybe more importantly, the last sitting in the room is the sales force. They're the guys that are out there that are fired up about it. And that's what we always want. It's that enthusiasm that drives the revenue.

Jim Sidoti: Right. And, you know, with regards to cash flow and another good quarter for cash flow, do you think you're at a point where you'll start to, pay down some of the debt going forward, or do you think you're going to keep the cash in the bank for additional deals?

It's, uh, it's something again. I've been watching for 10 years. Um, it's something that our physicians have encouraged us to look at because they use it. You need to have this. And finally, the right time came up and, uh, away we go. We, uh, we feel very good about the product, but maybe more importantly, the less sitting in the room is the sales force. They're the guys that are out there that are fired up about it, and that's what we always want. It's that enthusiasm that drives the revenue.

Fred Lampropoulos: Yeah. No, I mean, I'll, you know, I'll take this question and, you know, use it to highlight our free cash flow again, which was, you know, $90 million in a year to date, $70 million in the quarter, which is, you know, just fantastic. you know, for now, Jim, we'll we'll continue to, you know, to to hoard the cash, I'll say. we do have some capital expenditures that are coming in the back half of the year as we, you know, get, you know, get started on this building. I say started, but we've already got walls up, and, it's it's going to be coming at us here pretty quickly. And so, you know, we, but but for now, we'll.

Right. And, um, you know, with regards to cash flow and other another good quarter for cash flow, are you think you're at a point where you'll start to pay down some of the debt going forward? Or do you think you're going to keep the cash in the bank for additional deals?

Raul Parra: They're all in our forecast and.

Fred Lampropoulos: All in our forecast.

Raul Parra: In our guidance. They're in everything. So, so we're feeling pretty good about it. And, you know, yeah, continue to deliver a strong free cash flow. Again, I'll I'll highlight our operations group. I think it's doing a pretty good job of, you know, balancing the inventory, which is the primary driver of our working capital, allowing us to, you know, to to have these strong free cash flow numbers.

Yeah, no. I mean, I I, you know, I I'll take this question and and, you know, use it to highlight our free cash flow again which was, you know, 90 million dollars in the year to date 70 million in the quarter, uh, which is, you know, just fantastic. Um, you know, for now Jim, uh, we'll we'll continue to uh, you know, to to, to hoard the cash I'll say. Um, we do have some Capital expenditures that are coming in the back half of the year as we, you know, get um, you know, um, get started on this building and I say start it, but we've already got walls up and, um, it's, it's going to be coming at us here pretty quickly. And so, um, you know, we but but for now, they're all in our forecast and everything in our guidance, they're in everything so so, um, we're feeling pretty good about it and, um, you know, yeah, continue to deliver.

Jim Sidoti: Yep. All right. Thank you.

A strong free cash flow again I'll I'll highlight our operations group. I think is doing a pretty good job of you know um balancing the inventory uh which is the primary driver of our working capital um allowing us to you know to to have these strong free cash flow numbers.

Yep. All right. Thank you.

Operator: Thank you. And our next question will be coming from the line of Larry Beagleson of Wells Fargo. Your line is open.

Your line is open.

Lay (for Larry Biegelsen): Hi. It's Lay calling in for Larry Beagleson. Thanks for taking the question. my first one is just around your guidance update. So you beat Q2 revenue, by about 10 million. But at the midpoint of your guidance raise, on a cost-and-currency basis, the increase is less than 10 million. Is that all due to Rhapsody being, moved out six months, or is there anything else that changes about your second-half outlook? And I have another question after that.

Fred Lampropoulos: Sure. Sure. I mean, there's there's takes and puts, you know, across the board, you know, but, I think, you know, generally, our practice is to kind of look at the, you know, the first half beat and obviously, you know, flow some of that through. I think we ended up in a really good spot. Like you said, the midpoint of our updated guidance is about, you know, $10 million. I think we we all felt, you know, pretty good about where we're at. You know, there's a lot of uncertainty out there. I think the business continues to execute at a really high level, but just with all the tariffs and all the noise, there's a lot of things out there, you know, that, you know, just kind of give you a little bit of pause as as well as the business is doing.

Hi. It's uh, way calling for Larry. Be, thanks for taking the question. Um, my first one is just around your guidance update. So, you spoke to revenue, um, by about $10 million, but at the midpoint of your guidance, the increase on a constant currency basis is less than $10 million. Is that all due to Rapid City being, um, moved out six months, or is there anything else that changes about your second half outlook? And I have another question after that. Yes.

Fred Lampropoulos: So I'd say we feel pretty good about the guidance, and I think, it, it, it, you know, we have a high level of confidence in it. I'll just say that.

Lay (for Larry Biegelsen): Got it. Okay. That's helpful. And then, second question is around tariffs. Rob, I think in the past, you said you can, offset up to 45% of annualized tariffs for, in 2026. Is that still true? Any of, you know, any commentary on how we should think about tariffs for next year? Thank you.

Sure, sure. I I mean there's, there's takes and puts, you know, a cross the board, you know, but, um, I I think um, you know, generally our practice is just to kind of look at the, you know, the first half beat and obviously, um, you know, flow some of that through. I think we ended up in a really good spot. Like you said, the midpoint of our updated guidance is is about, um, you know, uh, 10 million dollars. Um, I I think we, we all felt, you know, pretty good about where we got, you know, there there's a lot of uncertainty out there. I, I think the business continues to execute, it really high level, but, uh, just with all the tariffs and all the noise, um, there's a lot of things out there, you know, that, you know, just kind of give you a little bit of pause, as well as the business is doing. So I, I, I'd say we feel pretty good about the guidance and I, I think, um, it it it, you know, it it we have a high level of confidence in it. I'll just say that.

Fred Lampropoulos: Yeah. I mean, I I would say that that was true, you know, based on that that initial assessment of what happened then, right? I I think we'll we feel pretty confident that we can overcome some of them. I I just have to see, quite frankly, where we end up at the end of the year. You know, what's what's real? What's, you know, what's a news headline? but I think we have a good game plan, and I would say nothing's changed from from that last update that we gave other than things have gotten a little bit better, and we've gotten some clarity, but it's still kind of a lot of moving parts. So I'll just say that I think our guidance, kind of contemplates everything that's out there right now, right, on the high end and the low end.

Okay, that's helpful. And then um second question questions around Paris. Well, I think in the past you said, you can um, offset up to 45% of annualized Parish for um in 2026. Is that still true? Any of, you know, any commentary on how we should think about terrorists for next year.

Fred Lampropoulos: and so we feel we feel pretty confident. And also, I'll just, you know, one one additional item is is we have not changed our CGI targets, right? We're still committed to those, which I think is really important.

Thank you. Yeah, I mean, I, I would say that. That was true, you know, um, based on that, that initial assessment of what happened then, right? Um, I, I think we'll what we feel pretty confident that we can overcome some of them. Um, I I just have to see quite frankly where we end up at the end of the year. You know what's what's real? What's uh, you know, what's the news headline? Um but I think we have a good game plan and I would say nothing's changed from from that last update that we gave. Other than things have gotten a little bit better. And we've gotten some clarity, but it's still kind of a lot of moving parts. So I'll just say that. I think our guidance um kind of contemplates everything that's out there right now, right on the high end and the low end. Um, and so we feel we feel pretty confident and also, I'll just, you know, 1 1 additional item is, is we have not changed our CGI targets, right? We're still committed to those.

Which I think is really important.

Operator: Thank you. And the next question will be coming from the line of Mike Metson of Needham & Company. Your line is open.

Raul Parra: Yeah. Thanks for taking my questions. I guess I'll ask one more on Rhapsody. Hopefully, this wasn't addressed earlier, but just you did say something about OBLs in the prepared remarks. And, you know, I'm just curious if, do you have any plan to pursue, you know, any additional reimbursement in the OBL setting? And, you know, how important is that? I mean, how many of these procedures are you even done in that setting?

Thank you. And the next question will be coming from the line of Mike Matson of Neiman Company. Your line is open.

Fred Lampropoulos: Yeah. Yeah. I mean, the.

Raul Parra: Go ahead.

Fred Lampropoulos: The focus is on, is on outpatient, right? It's the largest, you know, area of the market. And so I think that, that, you know, that's the biggest percentage. and that's where the focus is right now, Mike.

Yeah, thanks. Thanks for taking my questions. Um, I guess I'll ask one more on Rap City. Hopefully this wasn't addressed earlier, but just you, you did say something about OBL in the prepared remarks. And, uh, you know, just curious if, um, do you have any plans to pursue re, you know, any additional reimbursement in the OBL setting? And, um, you know how important is that? I mean, how many of these procedures are being done in that setting?

Yeah, yeah. I mean go ahead. The focus is on uh, is on outpatient, right? It's it's, it's the largest

You know, the area of the market. And so, I think that, you know,

Raul Parra: Okay. Got it. And then just just one more on the BioLife acquisition. So, you know, given the the nature of the products, are those going to be sold by, you know, in both the peripheral and the cardiac business? because I can imagine it could be used in both types of procedures, potentially. Yes. The answer is yes. It's used on radio procedures. It's used for PICC lines, ports, any place where you're bleeding and where you're, you know, where they're using those as we speak.

Fred Lampropoulos: Yeah. That's one of the exciting parts about that business when we when we acquired it is that it's it's one of the few products that we've acquired that really fits in just about every bag that we have.

It's, that's the biggest percentage. Um, and that, that's where the focus is right now, Mike. Okay, got it. And then, just one more on the Bayou Rights acquisition. So, you know, given the nature of the products, are those going to be sold by, you know, in both the peripheral and the cardiac business? Um, because I can imagine it could be used in both types of procedures, potentially? Yes, the answer is yes. It's used on radio procedures. It's used for pick lines, ports, any place where you're bleeding and where you're, you know, where if they're using those as we speak, that's one of the...

Raul Parra: Okay. And then just I think you referred to having some prior sort of some sort of prior hemostatic product that you guys were selling. So what were those, and how do those kind of fit with BioLife?

Exciting parts about that business, when we acquired it, is that it's one of the few products that we required that really fits in just about every bag that we have.

Okay. And then I think you referred to it having some prior.

Fred Lampropoulos: Well, yeah, some of these are things that actually work together. So if you take a look at this patch to stop the bleeding, they'll oftentimes use a sink and use this. In fact.

Sort of some sort of prior hemostatic product that you guys were selling. So what were those, and how do those kind of...

Raul Parra: Radio compression device.

Fred Lampropoulos: Yeah, radio compression device. So they'll use that and this to get faster hemostasis so that you can get to an ambulatory state and get them out of the, you know, out of the hospital. So, you know, they're they're often used. In fact, as I mentioned earlier, Mike, you know, this was something that physicians encouraged us to look at because they used it and say it would be nice just to buy this from one company, and some of it has a full suite of products. and that was something we said years ago, and we just kept following along until they finally aligned.

Raul Parra: Yeah. Got it. Thank you.

You know, this was something that physicians encouraged us to look at because they used it and said it would be nice just to buy this from one company. Some of it has a full suite of products, and that was something we said years ago. We just kept falling along until they finally aligned.

Fred Lampropoulos: Okay. Thanks, Mike.

Yeah, got it. Thank you.

Operator: Thank you. And the next question will be coming from the line of David Rescott of Beard. Your line is open.

Okay. Thanks. Mike.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Any of you guys hear me?

Thank you. And the next question will be coming from the line of David Reskit of Beard. Your line is open.

Fred Lampropoulos: Yeah, we got you, David.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Oh, great. Thanks for taking the question. I wanted to ask on the, you know, the guide for the year, particularly on the lower end of this EPS guide, since it, in general, is probably a good gauge of apples to apples from earlier in the year since you have the 26.3 million, in there from the tariff perspective. I guess, one, why I guess keep that, headwind at the low end if we're halfway through the year already and we know that, you know, China tariffs are significantly less than what they were a couple of months ago. So is there anything else, you know, in the other updated tariffs that are kind of getting you back to that 26.3? and then the second, part to this, I think you beat by 15, you know, cents or so.

And you guys hear me?

Yeah, we got you David.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): the lower end went up by, 24, I think, cents or so. So there's about a 10-cent delta of the, you know, underlying business versus BioLife. I think the the convert impact is the same. So can you just help us, you know, bridge the gap on on what was better in the quarter versus second half? Yeah.

Great. Um, thanks for for taking the question. Um, I wanted to ask on the, um, you know, the, the guide for the year, particularly on the the lower end of this EPS guide since it in general is probably a a good gauge of Apples to Apples. Um, from earlier in the year since you have the 26.3 million, uh, in there from the Tariff perspective. Um, I guess 1, uh, why, I guess keep that uh, headwind at at the low end, if we're halfway through the year already and we know that, you know, China tariffs are significantly less than what they were a couple months ago. So is there anything else, you know, in the other updated tariffs that are kind of getting you back to that 26.3? Uh, and then second, uh, part to this, um, I think you beat by 15, um, you know, cents or so. Uh, the lower end went up by uh, 24, I think cents or so. So there's about a 10 cent

Fred Lampropoulos: Yeah. I'll, I'll, I'll, I'll walk you through. So, right, so Q1, we had about a 14-cent beat. So we flowed that through. Q2, and this is obviously, I'm just talking strictly low end, so I don't want to confuse anybody. on the low end, we flowed through the 21 cents, you know, for Q2. and as you pointed out, we didn't make any changes to, to our tariff amount. and then you had an offset there, you know, for interest, expense that increased. So that's going to be 4 cents, and that's due to the, you know, obviously to the acquisition that we just did. and then, as you know, there were some tax changes, that were just signed, into law. And so that that'll be a 7-cent, impact also. So you, you know, you end up with the 24 cents that you that you just talked about.

Delta of the, you know, underlying business versus BioLife. I think the convertible impact is the same. So can you just help us, you know, bridge the gap on what was better in the quarter versus the second half?

Yeah, I'll walk you through. So, right, in Q1 we had about a 14-cent beat, so we flowed that through to Q2. And this is obviously, I'm just talking strictly low end, so I don't want to confuse anybody. Um, on the low end, we flowed through the 21 cents, um, you know, for Q2. Um, and as you pointed out, we didn't make any changes to our tariff amount.

Um, and then you had an offset there, you know, for interest expense that increased, so that's going to be 4 cents, and that's due to, you know, obviously, the acquisition that we just did.

Fred Lampropoulos: but this is, this is, you know, I'm glad you said what you said, you know, David, because this is exactly why we left the low end the way we did, because you just implied, right, that the, the, the China would be better. Well, that's just a rumor, right? That there's, that's, that's what, you know, that was a headline that came out, two days ago. There were two conflicting stories on it. we actually don't know if that's going to happen. I think the, the, the president said that it might. you know, so, I, you know, the, the, the, I think from our standpoint, still a lot of complexity to this, you know, and a lot of moving parts to it.

Um, and then, as you know, um, there was some tax changes, uh, that were just signed, um, into law. And so that that will be a 7 Cent, uh, impact also. So you, you know, you end up with a 24 cents that you that you just talked about. Um, but this is, this is, I, you know, I'm glad you said what you said, uh, you know, David because this is exactly why we left the low end the way we did. Because you just implied right? That the, the, the China would be better. Well, that's just a rumor, right? That there's that. That's that's what you know, that that was a headline that came out. Uh, 2 days ago, there was 2 conflicting stories on it. Um, we actually don't know if that's going to happen. Um, I think the the, the president said that it might, um, you know, so I you know that the the

Fred Lampropoulos: And I think we just felt like, the low end just reflects a high level of confidence in our 2025 outlook if there are significant changes to the tariffs, right? And, you know, so, so I think we felt comfortable just leaving it as is.

I think, from Marsh's standpoint, there is still a lot of complexity to this, you know, and a lot of moving parts to it. And I think we just felt like, um,

The low end just reflects a high level of confidence in our 2025 outlook.

Raul Parra: And you know, this is a point of interest. In FT, there's a big article today about the issue of the Chinese Navy and the increased tensions in the South China Sea. Yeah. Is that going to affect, you know, what's going on with tariffs in that dialogue? And the answer is absolutely. So again, who knows how that shakes out? You know, so I think we're taking the right approach. I agree with you, Raul. I mean, that's what we've talked about for a long time and, you know, several times in the last several days.

If there's significant changes to the tariffs, right? And, you know, so so I I think we, we felt comfortable just leaving it as this. And, you know, this is the point of interest in Ft. There's a big article today about the issue of the uh, Chinese Navy and the the increase tensions. In the South China Sea is that going to affect? Um you know what's going on with tariffs in that dialogue? And the answer is absolutely. So again, who knows how that shakes out

You know, I think we're taking the right approach. I agree with you. Well, I mean, that's what we've talked about for...

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Yeah. Okay. And then I might have missed it, you know, in the earlier Q&A. I know you set out earlier this year with the 7 to 9 for the contribution from Rhapsody. I believe at the time that didn't necessarily contemplate any reimbursement kind of uplift, whether it's TPT or NTAP. Have you reiterated that that contribution for the full year? And then, you know, how are or how is kind of the the sales force, in your view, responding maybe a little bit to to this delay in the reimbursement uplift? Does anything change on the commercial front over the next couple of months until you are able to to secure that if you are? Thank you.

A long time, and you know, several times in the last several days.

Okay. Um, and then, uh, I I might have missed it, um, you know, and, and the earlier Q&A, um, I I I know you set out earlier this year with the 7 to 9, UM, for the uh, contribution from Rap City. Uh, I believe at the time that didn't necessarily contemplate. Any reimbursement, kind of uplift. Uh, whether it's CBT or or, or untapped, um, have you reiterated that that contribution for the full year? And then, you know, how are or how is kind of the the sales force in your view responding? Maybe a little bit to, to this, uh,

Fred Lampropoulos: Well, I mean, no. So, right. So we updated our range to 2 to 4 million, David. I'm not sure if you caught that, but, and just just for the sake of clarity, our our guidance originally included all sorts of scenarios and assumptions, around the adoption and and utilization of of of these add-on, you know, reimbursement processes. And so, you know, clearly for for us now, we've got clarity on one. We still think that, you know, we're obviously going to use the comment period to to add additional color, you know, to CMS. and then we're also going to follow, you know, follow for for the additional add-on on the on the TPT.

Around the adoption. And utilization of, of, of these add-on, you know, reimbursement processes. And so, you know, clearly for, for us now, um,

Raul Parra: And, David, you know, as you know, we're just delayed six months on that one product. But let's talk about you asked about the sales force. You know, that RTG group is doing extraordinarily well. They have numerous products. We're seeing strength in all of those products across the board. So, yeah, I'm sure that you'd like to have everything in the bag, but they're doing very well and have plenty to sell, and all of those are doing well. So I've talked to several of the sales force, about, you know, their enthusiasm, about their targets, and this, that, and the other. And they're all, aligned, and they're all, I mean, I hate, I mean, I'll use the word, they're on fire. These sales guys are fired up because they have products that are distinct.

We've got Clarity on 1, we still think that, you know, obviously going to use the comment period to to add additional color, uh, you know, to CMS. Um, and then we're also going to follow, you know, follow for for the additional add-on on the, on the TPT. Yeah. Um, David, you know, as you know, we're just delayed 6 months and on that 1 product. But let's talk about, you asked about the sales force, you know, that RTG group is doing extraordinarily. Well, they have numerous products, we're seeing uh, strength in all of those products across the board. So, yeah, I'm sure that you'd like to have everything in the bag, but they're doing very well and have plenty to sell and all of those are doing well. So, I've talked to several of the sales force, um, about, you know, their enthusiasm about their targets and this that and the other and they're all, uh, aligned. And they're all, I mean, I I mean I'll use the word they're on fire. These sales guys are fired up because they have

Fred Lampropoulos: Yeah. And we're, we're, I mean, we're going to hold our premium pricing. Yeah, I know our competitors are not, and I think they're listening, but you know.

Raul Parra: Yeah. There's a few of them on the call. Yeah, four, to be exact. I was wondering when you were going to raise that. Okay. I hope that helps. Did that answer your question?

Have products that are distinct. Yeah I mean I mean we we were going to hold our premium pricing. Yeah, I know our competitors are not and I think they're listening but, you know, yeah. There's a, there's a few of them on the call 4 to be exact. I was wondering when you were going to raise that,

Fred Lampropoulos: Yes. Yeah, that's great. And I did miss the two to four updates, though. So thanks for clarifying that.

Okay, I hope that helps.

Raul Parra: Yeah, no problem.

Okay. Yes. That that that's great. And I I did miss the, the 2 to 4 update those. So thanks for clarifying that

Operator: Thank you. And the next question will be coming from the line of Michael Petinsky of Barrington Research. Your line is open.

Yeah, no problem.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Hey, good evening. Hey, so I wanted to ask, and maybe I missed a more fulsome explanation, but the language you're using around the China quarter is sort of similar to last quarter where you sort of say, well, soft macro environment just came in, you know, below what we thought, but not anything, unless I missed it, with real specificity. I'm just curious, like two soft quarters in China not related to EDP is not typical for you guys. And I'm just curious if you're digging into that or did I miss a more full explanation of that? Thanks.

Thank you. And the next question will be coming from the line of Michael Pinsky of Barington Research. Your line is open.

Hey.

Uh, hey, so I wanted to ask, and maybe I missed it.

An explanation. But

Fred Lampropoulos: Well, I mean, I think, well, I think the big explanation is that, you know, we continue to expect low single-digit growth in APAC for 2025, right? I mean, I think we've been very clear about that all year long. and China's a big contributor to that. and so, you know, I would say that, yes, it came in lower than expected, but also we just, it's China, right? There's just a lot of, you know, it's a tough macro environment, you know, there. And I would say that we've had quarters where we've done, you know, a better than anticipated, but I don't think anybody around here is kind of hitting the panic button, you know, Mike, to be honest with you. I mean, I just think it's just the environment we're in right now. it's not isolated to any one customer or any one, you know, segment.

China, the language you're using around to China quarter is sort of similar to last quarter where you sort of say, well, soft macro and firemen just came in, you know, below what we thought. But, but not anything, unless I missed it with real specificity. I'm just curious like 2 2 soft, soft quarters in China and not related to EDP is is not typical for you guys and I'm just curious if you're digging into that or or or did I miss a more, uh, full explanation of that? Thanks. Well, I mean, I, I think, well, I think the, the big explanation is that, you know, we continue to expect low single digit growth in APAC for 2025, right? I mean, I think we've been very clear about that. All all year long. Um, and

China's a big contributor to that. Um, and so, you know, I would say that yes, it came in lower than expected, but also.

we, we just

It it's it's China, right? There's just a lot of, you know, it's a it's it's a, it's a tough macro environment, you know, there. And, um, I would say that we've had quarters where we've done, you know, better than anticipated, but

Fred Lampropoulos: It's just a general softness. And, that's all, you know, that's all I have to say to it. You know, and obviously, volume-based purchasing, continues to be, a headwind, and, as we've talked about over the last, you know, couple of years.

I I don't think anybody around here has kind of hitting the the panic button, uh, you know, Mike, to be honest with you. I mean, I just think it's it's just the environment we're in right now. Um, it's it's not isolated to any 1 customer or any, any 1, you know, segment. It's just, it's just a general softness. And, um,

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Okay. And I just want to ask a quick question, and it's hard to keep track of how long any of these tariffs were actually on in the second quarter, but was is any of the 7 million, was it actually, like, did any of that actually hit in Q2? Was there an impact from that?

That's all, you know, that's all I have to say to it. You know, obviously volume based purchasing uh, continues to be. Um, I had 1 and, um, as as we as we've talked about over the last, you know, couple of years.

Fred Lampropoulos: Yeah, we had about $2 million that flowed through that's included in the gross margin.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): You said 2 million?

Okay, and I just want to ask a quick question and it's it's hard to keep track of how long any of any of these tariffs were actually on in the second quarter. But what is any of the 7 million was? It actually like, did any of that actually hit in Q2 was, was there an impact from the? Yeah, we had about 2 million dollars that, that, that flowed through that's included in the gross margin.

Fred Lampropoulos: Yeah, or 1.2, sorry. 2 cents.

You said, 2 million?

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Okay. Gotcha. Okay. Thanks. And then just the last question for Fred. I'm just curious, you know, the balance sheet leverages, you know, despite you guys being fairly active the last couple of years, is still, you know, pretty low in part due to, you know, the good cash flows. I'm just curious, are there assets out there that are interesting? What are you seeing? What are you seeing in terms of valuation? Anything you can add on that would be great. Thanks.

Yeah, or 1.2. Sorry.

2 cents. Okay.

And then just the last question for for Fred, uh, uh, just curious, you know, the, the balance sheet Leverage is, You know, despite you guys being fairly active, the last couple years is still, you know, pretty low in part due to you know the good cash flow. Is it just curious are there assets out there that are interesting what what are you seeing? What are you seeing in terms of valuation? Um,

Raul Parra: I'll just be very broad. There are opportunities. We look at them. If they're right for Merit, we'll do something about it. If not, we'll just continue to march. We may have to wait 10 years like we did for one of them. They're out there, but it's got to be patient, and, but they're there.

Anything you can add on would be great. Thanks. Um, I'll just be very broad. There are opportunities. We look at them; if they're right for Merit, we'll do something about it. If not, we'll just continue to march.

We may have to wait 10 years, like we did for one of them.

Analyst (various: Jason Bednar, Robbie Marcus, David Rescott, Michael Petusky): Okay. Fair enough. Thanks, guys. I really appreciate it.

Yeah, they're out there, but okay, got to be patient. And, um, they're there.

Raul Parra: Thanks, Mike.

Operator: Thank you. And this concludes today's Q&A session. I would like to go ahead and turn the call back over to Fred for closing remarks. The floor is yours, sir.

Okay, fair enough. Thanks, guys. I really appreciate it. Thanks, Mike.

Raul Parra: Thank you very much. ladies and gentlemen, thank you very much for your time on such a busy day. You know, it's an interesting time for me. This will be the last, publicly held quarterly report that I will speak to. I'll still be involved in the company. I will be the executive chairman, after October 3rd, and I'll still be a member of the board for a number of years. But I I want to thank you for all that you've taught me. I want to thank you for all the scolding you've given me, and helped us as a business and brought things to our attention that were necessary. So best wishes to all of you. And again, thank you. And signing off now from Salt Lake City, Utah, the home of the 2034 Winter Olympics. Good evening.

I would like to go ahead and turn the call back over to Fred for closing remarks. The floor is yours, sir.

Thank you very much. Um, ladies and gentlemen, thank you very much for your time on such a busy day.

You know, it's an interesting time for me. This will be the last.

Uh, publicly held quarterly report that I will speak to. I'll still be involved in the company. I will be the Executive Chairman after October 3rd, and I'll still be a member of the board for a number of years. But I want to thank you for all that you've taught me. I want to thank you for all the scolding you've given me and helped us as a business and brought things to our attention that were necessary. So best wishes to all of you. And again, thank you, and signing off now from Salt Lake City, Utah, the home of the 2034.

Winter Olympics.

Operator: This concludes today's presentation. You may all disconnect.

Good evening.

This concludes today's presentation. You may all disconnect.